KATHERINE BEAN: Open Payments
NPI 1295346856 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,306 in 133 payments from 13 companies in 2025. Trend: 2023 $1,077 · 2024 $1,845 · 2025 $2,306
Food & beverage: $2,306
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 55 | $770 |
| Janssen Biotech, Inc. | 20 | $348 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $287 |
| Gilead Sciences, Inc. | 10 | $226 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $174 |
| PFIZER INC. | 6 | $117 |
| Madrigal Pharmaceuticals | 5 | $107 |
| Regeneron Healthcare Solutions, Inc. | 3 | $91 |
| Ardelyx, Inc. | 4 | $62 |
| Lilly USA, LLC | 3 | $60 |
Products named: RINVOQ, TREMFYA, ENTYVIO, XIFAXAN, REZDIFFRA, DUPIXENT, XELJANZ, CREON.
Industry payments across KY — which companies pay providers there.
